Fractyl Health (GUTS) Scheduled to Post Earnings on Tuesday

Fractyl Health (NASDAQ:GUTS) will announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.10. The company had revenue of $0.04 million for the quarter. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $2.47 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 7.46 and a current ratio of 7.46. The stock’s 50-day simple moving average is $2.67 and its two-hundred day simple moving average is $4.13. Fractyl Health has a twelve month low of $1.74 and a twelve month high of $14.50.

Insider Activity at Fractyl Health

In other news, insider Jay David Caplan sold 65,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total value of $188,500.00. Following the completion of the sale, the insider now owns 30,484 shares of the company’s stock, valued at approximately $88,403.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.